The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia
Open accessAbstract
Background: In hospitalized patients with coronavirus disease 2019 (COVID-19) pneumonia, progression to acute respiratory failure requiring invasive mechanical ventilation (MV) is associated with significant morbidity and mortality. Severe dysregulated systemic inflammation is the putative mechanism. We hypothesize that early prolonged methylprednisolone (MP) treatment could accelerate disease resolution, decreasing the need for intensive care unit (ICU) admission and mortality. Methods: We conducted a multicenter observational study to explore the association between exposure to prolonged, low-dose MP treatment and need for ICU referral, intubation, or death within 28 days (composite primary end point) in patients with severe COVID-19 pneumonia admitted to Italian respiratory high-dependency units. Secondary outcomes were invasive MV-free days and changes in C-reactive protein (CRP) levels. Results: Findings are reported as MP (n = 83) vs control (n = 90). The composite primary end point was met by 19 vs 40 (adjusted hazard ratio [aHR], 0.41; 95% CI, 0.24–0.72). Transfer to ICU and invasive MV were necessary in 15 vs 27 (P = .07) and 14 vs 26 (P = .10), respectively. By day 28, the MP group had fewer deaths (6 vs 21; aHR, 0.29; 95% CI, 0.12–0.73) and more days off invasive MV (24.0 ± 9.0 vs 17.5 ± 12.8; P = .001). Study treatment was associated with rapid improvement in PaO2:FiO2 and CRP levels. The complication rate was similar for the 2 groups (P = .84). Conclusion: In patients with severe COVID-19 pneumonia, early administration of prolonged, low dose MP treatment was associated with a significantly lower hazard of death (71%) and decreased ventilator dependence. Treatment was safe and did not impact viral clearance. A large randomized controlled trial (RECOVERY trial) has been performed that validates these findings. Clinical trial registration. ClinicalTrials.gov NCT04323592.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report
Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., et al. (2020) · doi:10.1101/2020.06.22.20137273 · Cited by 11,475
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Giamarellos-Bourboulis, E. J., Netea, M. G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.-E., Katsaounou, P., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.009 · Cited by 2,045 · cited 1×
“Corticosteroids are powerful anti-inflammatory drugs that could have a role in promoting the resolution of ARF in patients with severe COVID-19 infection [5].”
BackgroundHenry, B. M., de Oliveira, M. H. S., Benoit, S., Plebani, M., & Lippi, G. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-0369 · Cited by 1,964
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Czock, D., Keller, F., Rasche, F. M., & H??ussler, U. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00003 · Cited by 886 · cited 2×
“Apart from the different study design and setting, we speculate that this difference is possibly due to several factors: First, the RECOVERY trial uses a different drug (dexamethasone) at a lower dose, equivalent to ~32 mg of methylprednisolone [23].”
Cited by
Macrophages in Lung Injury, Repair, and Fibrosis
Cheng, P., Li, S., & Chen, H. (2021) · Cells · doi:10.3390/cells10020436 · Cited by 444
Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes
van Paassen, J., Vos, J. S., Hoekstra, E. M., Neumann, K. M. I., Boot, P. C., & Arbous, S. M. (2020) · Critical Care · doi:10.1186/s13054-020-03400-9 · Cited by 382
Simons, D., Shahab, L., Brown, J., & Perski, O. (2021) · Addiction · doi:10.1111/add.15276 · Cited by 371
Ruaro, B., Salton, F., Braga, L., Wade, B., Confalonieri, P., Volpe, M. C., Baratella, E., Maiocchi, S., & Confalonieri, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052566 · Cited by 300
Self-citation
Metadata
- Authors
- Salton, F., Confalonieri, P., Meduri, G. U., Santus, P., Harari, S., Scala, R., Lanini, S., Vertui, V., Oggionni, T., Caminati, A., Patruno, V., Tamburrini, M., Scartabellati, A., Parati, M., Villani, M., Radovanovic, D., Tomassetti, S., Ravaglia, C., Poletti, V., Vianello, A., Gaccione, A. T., Guidelli, L., Raccanelli, R., Lucernoni, P., Lacedonia, D., Foschino Barbaro, M. P., Centanni, S., Mondoni, M., Davì, M., Fantin, A., Cao, X., Torelli, L., Zucchetto, A., Montico, M., Casarin, A., Romagnoli, M., Gasparini, S., Bonifazi, M., D’Agaro, P., Marcello, A., Licastro, D., Ruaro, B., Volpe, M. C., Umberger, R., & Confalonieri, M.
- Venue
- Open Forum Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-09-12
- Volume
- 7
- Issue
- 10
- Pages
- ofaa421-ofaa421
- ISSN
- 2328-8957 (ISSN-L)
- OpenAlex
- W3085008014
- Cited by
- 161
- References
- 7
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.